JP2005526520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526520A5 JP2005526520A5 JP2004508299A JP2004508299A JP2005526520A5 JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5 JP 2004508299 A JP2004508299 A JP 2004508299A JP 2004508299 A JP2004508299 A JP 2004508299A JP 2005526520 A5 JP2005526520 A5 JP 2005526520A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- pharmaceutical composition
- muc
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102100006037 MUC1 Human genes 0.000 claims 5
- 101700052761 MUC1 Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003899 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
Claims (15)
- in vivoで免疫応答を生じる能力を有し、全長MUC-1より組換えを起こしにくい分子である、MUC-1抗原をコードする核酸分子。
- 1から15個までのVNTR完全反復ユニットを含むMUC-1抗原をコードする核酸分子。
- 8個未満の完全VNTR反復ユニットを含む、請求項２に記載の核酸分子。
- 少なくとも1個のVNTRが変異してグリコシル化の可能性が低下した、請求項１〜３のいずれか１項に記載の核酸分子。
- 次の群：FLSFHISNL、NSSLEDPSTDYYQELQRDISEおよびNLTISDVSVから選択されるエピトープをコードする配列を組み込んだ、請求項１〜４のいずれか１項に記載の核酸分子。
- 前記分子がDNA分子である、請求項１〜５のいずれか１項に記載の核酸分子。
- 請求項６に記載のDNA分子を含むプラスミド。
- 請求項１〜6のいずれか１項に記載の核酸分子によってコードされるタンパク質。
- 請求項１〜6のいずれか１項に記載の核酸分子、または請求項7に記載のプラスミド、または請求項８に記載のタンパク質、および製薬上許容される賦形剤、希釈剤もしくは担体を含む医薬組成物。
- 前記担体が微粒子である、請求項９に記載の医薬組成物。
- 前記微粒子が金である、請求項１０に記載の医薬組成物。
- アジュバントを含む、請求項９〜１１のいずれか１項に記載の医薬組成物。
- 医薬において使用するための、請求項１〜６のいずれか１項に記載の核酸、請求項7に記載のプラスミド、請求項８に記載のタンパク質、または請求項９〜１２のいずれか１項に記載の医薬組成物。
- MUC-1を発現する腫瘍の治療もしくは予防のための薬剤の調製における、請求項１〜６のいずれか１項に記載の核酸の使用。
- MUC-1を発現する腫瘍の治療もしくは予防のための薬剤の製造における、請求項８に記載のタンパク質の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212046.7A GB0212046D0 (en) | 2002-05-24 | 2002-05-24 | Vaccines |
| PCT/EP2003/005594 WO2003100060A2 (en) | 2002-05-24 | 2003-05-23 | Muc-1 antigen with reduced number of vntr repeat units |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526520A JP2005526520A (ja) | 2005-09-08 |
| JP2005526520A5 true JP2005526520A5 (ja) | 2006-06-08 |
Family
ID=9937394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508299A Pending JP2005526520A (ja) | 2002-05-24 | 2003-05-23 | Ｖｎｔｒ反復ユニットの数が減少したｍｕｃ−１抗原 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060251665A1 (ja) |
| EP (1) | EP1527177A2 (ja) |
| JP (1) | JP2005526520A (ja) |
| KR (1) | KR20050004211A (ja) |
| CN (1) | CN100408682C (ja) |
| AR (1) | AR039846A1 (ja) |
| AU (1) | AU2003240729B2 (ja) |
| BR (1) | BR0311211A (ja) |
| CA (1) | CA2485816A1 (ja) |
| GB (1) | GB0212046D0 (ja) |
| IL (1) | IL165156A0 (ja) |
| IS (1) | IS7526A (ja) |
| MX (1) | MXPA04011527A (ja) |
| NO (1) | NO20044947L (ja) |
| NZ (1) | NZ536668A (ja) |
| PL (1) | PL374569A1 (ja) |
| RU (1) | RU2303069C2 (ja) |
| TW (1) | TW200407426A (ja) |
| WO (1) | WO2003100060A2 (ja) |
| ZA (1) | ZA200409445B (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| JP5285855B2 (ja) * | 2003-11-12 | 2013-09-11 | アメリカ合衆国 | 膵癌を処置および予防するためのカスタムベクター |
| ES2476990T3 (es) * | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| CA2595778A1 (en) * | 2005-01-28 | 2006-08-03 | Ramot At Tel Aviv University, Ltd. | Anti-muc1 .alpha..beta. antibodies |
| US20120039984A1 (en) | 2008-07-03 | 2012-02-16 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| CN103209701B (zh) * | 2010-06-11 | 2016-08-03 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| CN106215179A (zh) * | 2010-06-11 | 2016-12-14 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| CN103781469B (zh) * | 2011-02-24 | 2015-09-16 | 肿瘤防护公司 | 含有佐剂的以muc1为基础的糖脂肽疫苗 |
| CA2954892A1 (en) * | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| RU2756534C2 (ru) | 2016-09-28 | 2021-10-01 | Бавариан Нордик А/С | Композиции и способы для повышения стабильности трансгенов в поксвирусах |
| RS64379B1 (sr) | 2018-05-18 | 2023-08-31 | Glycotope Gmbh | Anti-muc1 antitelo |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1012276A2 (en) * | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| AU778701B2 (en) * | 1999-09-08 | 2004-12-16 | Imperial Cancer Research Technology Ltd | MUC-1 derived peptides |
| GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| JP2003533181A (ja) * | 2000-02-01 | 2003-11-11 | ジ・オースティン・リサーチ・インスティテュート | ムチン−１誘導抗原および免疫療法におけるその使用 |
| US20020142047A1 (en) * | 2001-01-19 | 2002-10-03 | Johnson Mark E. | Microsphere delivery of mucin peptides |
| US7125663B2 (en) * | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| EP1572918B1 (en) * | 2002-04-15 | 2011-10-19 | Oncothyreon Inc. | Synthetic glyco-lipo-peptides as vaccines |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
-
2002
- 2002-05-24 GB GBGB0212046.7A patent/GB0212046D0/en not_active Ceased
-
2003
- 2003-05-22 AR ARP030101782A patent/AR039846A1/es unknown
- 2003-05-22 TW TW092113870A patent/TW200407426A/zh unknown
- 2003-05-23 PL PL03374569A patent/PL374569A1/xx unknown
- 2003-05-23 KR KR10-2004-7018958A patent/KR20050004211A/ko not_active Application Discontinuation
- 2003-05-23 WO PCT/EP2003/005594 patent/WO2003100060A2/en active Application Filing
- 2003-05-23 US US10/515,871 patent/US20060251665A1/en not_active Abandoned
- 2003-05-23 CN CNB038171988A patent/CN100408682C/zh not_active Expired - Fee Related
- 2003-05-23 MX MXPA04011527A patent/MXPA04011527A/es not_active Application Discontinuation
- 2003-05-23 NZ NZ536668A patent/NZ536668A/en unknown
- 2003-05-23 AU AU2003240729A patent/AU2003240729B2/en not_active Ceased
- 2003-05-23 BR BR0311211-0A patent/BR0311211A/pt not_active IP Right Cessation
- 2003-05-23 RU RU2004134331/13A patent/RU2303069C2/ru active
- 2003-05-23 EP EP03730134A patent/EP1527177A2/en not_active Withdrawn
- 2003-05-23 JP JP2004508299A patent/JP2005526520A/ja active Pending
- 2003-05-23 CA CA002485816A patent/CA2485816A1/en not_active Abandoned
-
2004
- 2004-11-10 IL IL16515604A patent/IL165156A0/xx unknown
- 2004-11-11 IS IS7526A patent/IS7526A/is unknown
- 2004-11-12 NO NO20044947A patent/NO20044947L/no not_active Application Discontinuation
- 2004-11-23 ZA ZA200409445A patent/ZA200409445B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526520A5 (ja) | ||
| JP6124267B2 (ja) | フィブロネクチン３型ドメインに基づくスカフォールド組成物、方法及び使用 | |
| JP5873335B2 (ja) | フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用 | |
| JP2008508859A5 (ja) | ||
| JP2010500399A5 (ja) | ||
| JP2008530245A5 (ja) | ||
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| JP2016539946A5 (ja) | ||
| JP2009292810A5 (ja) | ||
| JP2006141398A5 (ja) | ||
| JP2009515831A5 (ja) | ||
| CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
| HUP0401534A2 (hu) | Módosított humán IX. faktor | |
| JP2008056679A5 (ja) | ||
| DE60014076D1 (de) | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid | |
| JP2005538932A5 (ja) | ||
| JP2008535800A5 (ja) | ||
| JP2015501840A5 (ja) | ||
| JP2016513115A5 (ja) | ||
| JP2005511019A5 (ja) | ||
| JP2002542827A5 (ja) | ||
| JP2005102701A5 (ja) | ||
| RU2004134331A (ru) | Антиген muc1 со сниженным числом повторяющихся vntr-блоков | |
| JP2019531293A5 (ja) | ||
| WO2003039225A3 (en) | Antigen arrays comprising rankl for treatment of bone disease |